Cordis Comes Back for Another Stent

Cordis is getting back into the coronary stent game. The company, which is now owned by Cardinal Health, landed exclusive rights to sell Medinol's coronary stent portfolio in the U.S. Milpitas, CA-based Cordis is already selling Medinol's NIRxcell cobalt-chromium bare-metal stent and, assuming FDA approves Medinol's EluNIR drug-eluting stent (DES), Cordis will distribute it as well. Medinol is based in Israel. In addition to the Medinol agreement, Cordis recently launched the Tryton Side Branch Stent and two percutaneous transluminal coronary angioplasty (PTCA) balloon catheters. The Medinol agreement, along with the availability of the Tryton stent and Meril PTCA balloon catheters, reestablishes Cordis in the U.S. market with a significant interventional cardiology portfolio, said Peter Van Haur, vice president of North America sales and marketing at the company. "By adding these new products to our portfolio, we can make the most significant contribution to the healthcare system and deliver the innovative products and solutions that our customers and their patients are seeking," he said. Cordis used to be one of the biggest players in the coronary stent market under Johnson &Johnson, but J&J decided to quit making stents in 2011. At the time, the company said the decision was due to evolving market dynamics in the drug-eluting stent business, including lower demand, pricing and reimbursement pressure, and a stringent regulatory environment. Dubl...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Source Type: news

Related Links:

AbstractThis paper empirically investigates the impact of additional reimbursement instruments on the diffusion of new technologies in inpatient care. Using 2010 –2014 German panel data on hospital level for every patient undergoing coronary angioplasty, this study examines the utilisation of drug-eluting balloon catheters (DEB) over time while additional payment instruments changed. Hypothesising that the utilisation of DEB increased abruptly when a new r eimbursement instrument came into force, we estimate a fixed effects regression comparing years with a change and years where the reimbursement instrument remained...
Source: The European Journal of Health Economics - Category: Health Management Source Type: research
CONCLUSION:  Cangrelor produces more potent P2Y12 inhibition at the time of first coronary balloon inflation time compared with ticagrelor. Despite this enhanced P2Y12 inhibition, coronary microvascular function and final infarct size did not differ between groups. PMID: 31129911 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Tags: Thromb Haemost Source Type: research
Blue arrows: edges of stent; red arrows: balloon edge markers (there will be an overhang of the balloon beyond the markers on either side); yellow arrow: guide catheter; violet arrow: angioplasty guide wire. Guide catheter is in left main coronary artery, guidewire and stent in left anterior descending coronary artery. Accurate visualization of the stent position and morphology is essential for good implantation technique. Stent has to be well expanded and apposed to the vessel wall to prevent stent thrombosis. But good visualization in a moving vessel is often challenging. Selecting a good view with less of movement is ...
Source: Cardiophile MD - Category: Cardiology Authors: Tags: Coronary Interventions Stent boost subtract imaging Source Type: blogs
ConclusionAcute limb ischemia caused by an EXOSEAL vascular closure device is a very rare complication. Balloon angioplasty and stenting are considered to be effective options to deal with the plug dislodgement of an EXOSEAL vascular closure device. We must be prepared for every rare complication during endovascular treatment.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
By SOMALARAM VENKATESH MD With a stated intent of bringing social justice and financial relief to hundreds of thousands of patients undergoing coronary angioplasty in the country every year, the Government of India capped the sale price of coronary stents in Feb 2017. Stent prices fell by as much as 80% with this populist move, seen as anti-trade within the industry circles. It is tempting for a practising interventional cardiologist to look at two years of this government control on medical device prices in a market economy. Before price-capping, angioplasty patients were indeed getting a raw deal. There was no uniformity...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Health Policy Physicians cardiology coronary stent prices India Somalaram Venkatesh Source Type: blogs
Rescue Percutaneous Coronary Intervention for a Lethal "Jailed" Septal Perforator Branch to Resolve Delayed Complete Atrioventricular Block. Int Heart J. 2019 Feb 22;: Authors: Nojima Y, Ihara M, Adachi H, Kurimoto T, Nanto S Abstract Delayed complete atrioventricular (AV) block associated with an occluded septal perforator branch (SPB) is an uncommon complication after performing percutaneous coronary intervention (PCI) for the left anterior descending coronary artery (LAD). Here we report the case of a 74-year-old man who underwent elective PCI for proximal LAD complicated with occlusion of...
Source: International Heart Journal - Category: Cardiology Tags: Int Heart J Source Type: research
Stingray" Guidewire, labeled as 300cm. intended to facilitate placement of balloon dilatation catheters or other intravascular devices during percutaneous transluminal coronary angioplasty (PTCA) and percutaneous transluminal angioplasty (PTA).
Source: Medical Device Recalls - Category: Medical Devices Source Type: alerts
We present our early real-world experience with the S-IVL device. METHODS: All patients treated with S-IVL between October 2018 and January 2019 during their percutaneous coronary intervention (PCI) at our center were included. RESULTS: During this period, a total of 26 patients undergoing PCI were treated with S-IVL prior to stent deployment (69% male; age, 72 ± 8 years). Indications for PCI were acute coronary syndromes (ACS) in 14 patients (54%), stable angina in 11 patients (42%), and PCI before transcatheter aortic valve implantation in 1 patient (4%). Seventy-one percent of the ACS cases undergoing PCI...
Source: The Journal of Invasive Cardiology - Category: Cardiology Tags: J Invasive Cardiol Source Type: research
Cardiologists are grappling with at least  half a dozen time windows  in the management of STEMI. (It can be combinations of any of the following :Symptom – DAPT Loading – Door – Needle /Balloon-Sheath, wire crossing etc ) Time windows are Important in choosing the right (or no)modality of re-perfusion . Though superiority of  primary PCI  is thought to be established in academic community , it  may not be in real world. Published studies that suggest pPCI is superior to lysis at any time window  still lack good evidence. Why is this long drawn confusion&n...
Source: Dr.S.Venkatesan MD - Category: Cardiology Authors: Tags: cath lab tips and tricks PCI PTCA Hardware Primary -PCI STEMI STEMI -Managment STEMI-Primary PCI Thrombolysis how to estimate the age of thrombus in stemi acs soft vs hard thrombus in stemi thrombus hardening time thrombus organising t Source Type: blogs
ObjectivesTo determine whether a variation of an abandoned antegrade percutaneous coronary intervention (PCI) technique, termed subintimal tracking and reentry (STAR), could be a safe and effective strategy to contend with complex coronary chronic total occlusions (CTO) when other strategies fail.BackgroundComplex CTOs require advanced techniques such as the retrograde approach, which is associated with higher complication rates than antegrade strategies.MethodsThe medical records of 32 consecutive patients who underwent deferred stenting following STAR (DSS) between January 2015 and May 2017 at a high ‐volume referral c...
Source: Catheterization and Cardiovascular Interventions - Category: Cardiovascular & Thoracic Surgery Authors: Tags: CORONARY ARTERY DISEASE Source Type: research
More News: Angioplasty | Baloon Angioplasty | Canada Health | Cardiology | Cardiovascular | Chromium | Clinical Trials | Cobalt | Coronary Angioplasty | Environmental Health | Heart | Israel Health | Marketing | Medical Devices | Middle East Health | Study | USA Health